The second issue lies with the concept of sampling, as the participants in the study were drawn from a convenience sample from an access research panel, and is unlikely that such a sample would be representative of the general population. Persons
with arthritis in Australia have marked impairments in quality of life characterized by difficulty with many aspects of daily activity. These impairments are more stark when put in the context of some other common and morbid diseases. Despite significant impairments in pain and quality selleckchem of life, many persons have not discussed their pain with their GP and many don’t take prescribed treatments due largely to concerns over potential side effects. This platform provides ample opportunity for increased awareness of the disease and increased knowledge about the potential for improved management. DJH participated in the design of the survey and drafted the manuscript. ER participated
in drafting CX-5461 mw the manuscript. Both authors read and approved the final manuscript. We would like to thank the participants in this survey without whom this work would not have been possible. Dr Hunter is funded by an ARC Future Fellowship. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. This project was initiated and funded by AstraZeneca Pty Ltd (Australia). The Pain and Mobility Index conducted by Hall & Partners was coordinated by Scaffidi Hugh-Jones on behalf of AstraZeneca Pty Ltd (Australia). “
“The aim of this study was to investigate the incidence of tuberculosis (TB) following Methocarbamol anti-tumor necrosis factor (TNF) therapy in an intermediate TB burden area and to compare the risk between drugs and diseases. The data were obtained from a nationwide database maintained by the Health Insurance Review and Assessment Service. The study population comprised of patients
who were prescribed with TNF inhibitors from 2005 to 2009. TB cases were selected based on prescription of anti-TB medications. Of 8421 patients in the study population, 1729 patients with latent TB prophylaxis were identified and 102 patients developed TB. The incidence of TB was 1017 per 100 000 person-years. When divided into four groups according to the main diagnosis and using an ankylosing spondylitis group as a reference, the incidence of TB was highest in patients with inflammatory bowel disease (IBD) (incidence rate ratio [IRR] 5.97, 95% confidence interval [CI] 3.34–10.66), followed by patients with rheumatoid arthritis (IRR 1.02, 95% CI 0.57–1.83) and those with psoriatic arthritis (IRR 1.00, 95% CI 0.14–7.30).